key: cord-0994679-qhnqqae6
authors: Ferrante, Giuseppe; Fazzari, Fabio; Cozzi, Ottavia; Maurina, Matteo; Bragato, Renato; D’Orazio, Federico; Torrisi, Chiara; Lanza, Ezio; Indolfi, Eleonora; Donghi, Valeria; Mantovani, Riccardo; Liccardo, Gaetano; Voza, Antonio; Azzolini, Elena; Balzarini, Luca; Reimers, Bernhard; Stefanini, Giulio G; Condorelli, Gianluigi; Monti, Lorenzo
title: Risk factors for myocardial injury and death in patients with COVID-19: insights from a cohort study with chest computed tomography
date: 2020-07-08
journal: Cardiovasc Res
DOI: 10.1093/cvr/cvaa193
sha: a47b0413b792021187ff25ca26f6eaf0dd8624b8
doc_id: 994679
cord_uid: qhnqqae6

AIMS: Whether pulmonary artery (PA) dimension and coronary artery calcium (CAC) score, as assessed by chest computed tomography (CT), are associated with myocardial injury in patients with coronavirus disease 2019 (COVID-19) is not known. The aim of this study was to explore the risk factors for myocardial injury and death and to investigate whether myocardial injury has an independent association with all-cause mortality in patients with COVID-19. METHODS AND RESULTS: This is a single-centre cohort study including consecutive patients with laboratory-confirmed COVID-19 undergoing chest CT on admission. Myocardial injury was defined as high-sensitivity troponin I >20 ng/L on admission. A total of 332 patients with a median follow-up of 12 days were included. There were 68 (20.5%) deaths; 123 (37%) patients had myocardial injury. PA diameter was higher in patients with myocardial injury compared with patients without myocardial injury [29.0 (25th–75th percentile, 27–32) mm vs. 27.7 (25–30) mm, P < 0.001). PA diameter was independently associated with an increased risk of myocardial injury [adjusted odds ratio 1.10, 95% confidence interval (CI) 1.02–1.19, P = 0.01] and death [adjusted hazard ratio (HR) 1.09, 95% CI 1.02–1.17, P = 0.01]. Compared with patients without myocardial injury, patients with myocardial injury had a lower prevalence of a CAC score of zero (25% vs. 55%, P < 0.001); however, the CAC score did not emerge as a predictor of myocardial injury by multivariable logistic regression. Myocardial injury was independently associated with an increased risk of death by multivariable Cox regression (adjusted HR 2.25, 95% CI 1.27–3.96, P = 0.005). Older age, lower estimated glomerular filtration rate, and lower PaO(2)/FiO(2) ratio on admission were other independent predictors for both myocardial injury and death. CONCLUSIONS: An increased PA diameter, as assessed by chest CT, is an independent risk factor for myocardial injury and mortality in patients with COVID-19. Myocardial injury is independently associated with an approximately two-fold increased risk of death.

Myocardial injury, as defined by cardiac troponin elevations above the normal values, has been reported in 19 .7% and 27.8% of patients hospitalized for coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in two recent Chinese studies. 1, 2 Of note, patients with myocardial injury were older and presented with more comorbidities, including hypertension, diabetes, and cardiovascular disease, in comparison with patients without myocardial injury. 1, 2 Guo et al. also found an association of myocardial injury with systemic inflammatory indices, such as C-reactive protein and N-terminal probrain natriuretic peptide (NT-proBNP). 1 In both studies, patients with myocardial injury had a higher short-term mortality than patients without myocardial injury. 2 Nevertheless, whether these findings are generalizable to other countries during the COVID-19 pandemic is largely unknown.

Further, the identification of patients at high risk of myocardial injury may have clinical implications, and a better understanding of the factors associated with myocardial injury is of paramount importance. Several putative mechanisms underlying myocardial injury have been hypothesized, including inflammatory damage of the heart, a direct viral effect, the trigger of acute coronary events, and the onset of acute decompensated heart failure precipitated by the COVID-19 infection. 3, 4 Chest computed tomography (CT), without contrast administration, is the reference imaging tool routinely used for the diagnosis of COVID-19 pneumonia and may provide additional cardiovascular parameters of potential clinical relevance, such as the pulmonary artery (PA) dimension 5 and the coronary artery calcium (CAC) score. 6 PA dimension has been shown to be associated with cardiac troponin elevations in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease and has been related to pulmonary vascular damage. 7 COVID-19 may lead to respiratory failure, [8] [9] [10] [11] and pulmonary endothelial damage usually affects patients with acute respiratory distress syndrome (ARDS). 12 It is not known whether PA dimension is associated with myocardial injury. The CAC score is an established marker of atherosclerotic burden that has been shown to improve cardiovascular risk prediction in asymptomatic individuals. 13 No study has assessed whether the CAC score may improve the identification of patients at risk of myocardial injury, beyond the assessment of the clinical risk profile in COVID-19 patients.

The aim of this study was to provide insights into the factors associated with myocardial injury in patients hospitalized with COVID-19 by integrating clinical data, biochemical markers, and CT data, and to investigate the impact of myocardial injury on mortality as well as the predictors of mortality.

This is a single-centre cohort study enrolling consecutive patients with a diagnosis of confirmed COVID-19, admitted to an academic tertiary hospital (Humanitas Research Hospital) undergoing non-gated chest CT for the assessment of COVID-19-related pneumonia, between 25 February and 2 April 2020. This time window was considered sufficient for the enrolment of >300 patients, given the COVID-19 outbreak. Laboratory confirmation for SARS-CoV-2 required a positive result of a real-time reverse transcriptionpolymerase chain reaction (RT-PCR) assay of nasal and pharyngeal swabs or a positive result of RT-PCR assay from lower respiratory tract aspirates or bronchoalveolar lavage fluid. The study was approved by the institutional Ethics Committee which waived the requirement to obtain an informed consent from individual patients due to retrospective chart reviews. The investigation conformed to the principles outlined in the Declaration of Helsinki.

Data were collected using electronic heath records by staff who were not aware of the study hypothesis in order to reduce the risk of bias. Data included demographic characteristics (age and sex), clinical data fcardiovascular risk factors and comorbidities including prior history of coronary artery disease, history of cerebrovascular disease defined as prior stroke or carotid artery disease, peripheral artery disease, chronic obstructive pulmonary disease, cancer, respiratory metrics [i.e. fraction of inspired oxygen (FiO 2 ), arterial partial pressure of oxygen (PaO 2 ), PaO 2 /FiO 2 ratio on admission], mode of respiratory support (invasive mechanical ventilation, noninvasive mechanical ventilation, oxygen mask)g, laboratory data [creatinine, C-reactive protein, systemic inflammatory biomarkers, D-dimer, cardiac biomarkers such as high-sensitivity troponin (hsTn)-I and BNP], treatments, and outcomes.

Hypertension was defined as a history of systolic blood pressure of > _140 mmHg, or a diastolic blood pressure of > _90 mmHg, or taking antihypertensive medications. Dyslipidaemia was defined as a history of elevated total or LDL cholesterol levels, low levels of HDL cholesterol, elevated triglycerides, or taking lipid-lowering medications. Current smokers were defined as having smoked 100 cigarettes in their lifetime and currently smoking, former smokers as having smoked at least 100 cigarettes in their lifetime but who had quit smoking in the last 28 days. Diabetes mellitus was defined as a history of diabetes or taking antidiabetic medications. A new diagnosis for each condition during hospitalization was also considered. Cardiac biomarkers were measured within 48 h from admission. Patients were categorized according to the presence or absence of myocardial injury, which was defined as blood levels of hsTn-I above the 99th percentile upper reference limit (20 ng/L), regardless of new abnormalities on electrocardiography and echocardiography. The last date of follow-up was 10 April 2020. The clinical outcomes included discharge, length of stay, intensive care unit admission, and mortality.

Patients were imaged on a dedicated 64-slice CT scanner (Philips Ingenuity Core) on admission. All CT scans were acquired without electrocardiographic gating and without contrast administration. Images were reconstructed at 2 mm thick slices on three orthogonal planes. The CT scans were read independently by two experienced readers, who were blinded for all clinical data to reduce the risk of bias, for the pulmonary and aortic dimensions, and the CAC score using a dedicated offline cardiac workstation (HeartBeat-CS IntelliSpace Portal, Philips). The transverse axial diameter of the main PA and the ascending aorta at the level of the bifurcation of the right PA were measured as previously reported. 5 The ratio of PA to aorta was calculated as the ratio of the main PA to the ascending aorta diameter. CAC was assessed as quantitative CAC score (Agatston scoring), which has been shown to have a high correlation with gated CT studies and cardiovascular disease outcomes. 6 Traditional CAC score groups (0, 1-100, 101-400, and >400) were obtained. Patients were categorized according to the presence or absence of a CAC score of zero. 6 Outcomes Two co-primary endpoints were defined: the occurrence of myocardial injury and death from any cause. Secondary outcomes were the duration of hospitalization and admission to an intensive care unit.

Baseline and procedural characteristics were summarized according to myocardial injury. Continuous variables were summarized as medians with interquartile ranges, and counts with proportions for categorical variables.

.

Continuous variables were compared using the Wilcoxon rank-sum test, and categorical variables were compared using the Pearson v 2 test or Fisher exact test, as appropriate. Study outcomes were compared using the same tests, as appropriate. A multivariable logistic regression model was used to assess the predictors of myocardial injury. Variable selection was done based on prior knowledge from the literature and was confirmed by using a backward selection method maintaining the number of events per variable at >10 (Model 1). An additional model was used as a sensitivity analysis (Supplementary material online, Appendix). 14 The results are presented as odds ratios (ORs) and 95% confidence intervals (CIs). A multivariable Cox proportional hazards model was used to assess the adjusted association between myocardial injury and mortality at the longest follow-up and to assess predictors of mortality. The results are presented as hazard ratios (HRs) and 95% CIs. Mortality was displayed by using cumulative incidence curves and compared between patients with and without myocardial injury, after adjusting for the multivariable Cox regression model. The statistical level of significance was a two-tailed P-value <0.05. STATA 16 statistical software (Statacorp LP, College Station, TX, USA) was used for all calculations. Details of the statistical analysis are reported in the Supplementary material online, Appendix.

Of 445 patients with confirmed COVID-19 admitted to our Institution from 25 February 2020 to 2 April 2020, a total of 349 patients underwent chest CT; of these, 17 patients with missing core results of laboratory examination (hsTn-I) were excluded. Finally, the overall study population consisted of 332 patients with availability of CT data and hsTn-I levels. The main clinical characteristics of the patients initially screened, of those who were excluded, and of those who entered the study are reported in Supplementary material online, Table 1 .

Baseline detailed characteristics of patients finally included in the study according to the presence of myocardial injury are displayed in Table 1. A total of 123 out of 332 (37%) patients had myocardial injury and 209 (63%) had no myocardial injury. Patients with myocardial injury were significantly older [74 (68-80) vs. 61 (51-70) years; P < 0.001], and had a higher prevalence of comorbidities including hypertension (76% vs. 41%; P < 0.001), diabetes mellitus (29% vs. 17%; P ¼ 0.014), prior coronary artery disease (28% vs. 7%; P < 0.001), history of stroke or carotid artery disease (24% vs. 3%; P < 0.001), and peripheral arterial disease (11% vs. 2%; P < 0.001) than patients without myocardial injury.

Creatinine levels were higher [1.11 (0.79-1.60) vs. 0.88 (0.72-1.06) mg/ dL, P < 0.001] and estimated glomerular filtration rate (eGFR) was lower [64 (40-87) vs. 88 (72-102) mL/min, P < 0.001] in patients with myocardial injury as compared with patients without myocardial injury (Table 1) . Patients with myocardial injury had higher levels of C-reactive protein, D-dimer, and BNP in comparison with patients without myocardial injury ( Table 1) . White blood count was similar, and lymphocyte count and haemoglobin levels were lower in patients with myocardial injury as compared with patients without myocardial injury (Table 1) . Table 2 summarizes CT findings. PA diameter was higher in patients with as compared with patients without myocardial injury [29.0 mm (27-32) vs. 27.7 (25-30) mm, P < 0.001]. No significant differences were found in the PA/aorta ratio between the two groups ( Table 2) . Patients with myocardial injury had a lower prevalence of a CAC score of zero (25% vs. 55%, P < 0.001), and higher median values of CAC score in comparison with patients without myocardial injury [108 (0-389) vs. 0 (0-78), P < 0.001]. The prevalence of a CAC score of 101-400 and >400 was higher in patients with cardiac injury as compared with those without (Table 2 ).

The PaO 2 /FiO 2 ratio was lower in patients with myocardial injury in comparison with patients without myocardial injury [252 (171-329) vs. 300 (214-374), P ¼ 0.005]. The prevalence of a PaO 2 /FiO 2 ratio of 0-100, 101-200, and 201-300, and the need for mechanical ventilation was significantly higher in patients with myocardial injury than in patients without myocardial injury (Table 3) .

A small subset of 21 patients underwent echocardiography during hospitalization. The main echocardiographic data are reported for descriptive purposes in Supplementary material online, Table 2 . Patients with myocardial injury presented a larger right ventricular dimension compared with patients without myocardial injury.

By multivariable regression analysis, age (OR 1.05, P ¼ 0.001), hypertension (OR 2.72, P ¼ 0.009), history of cerebrovascular disease (OR 3.33, P ¼ 0.01), eGFR (OR 0.98, P ¼ 0.006), the PaO 2 /FiO 2 ratio, as categorical variable (OR 1.35, P ¼ 0.03), and PA diameter (OR 1.10, P ¼ 0.012) emerged as independent predictors of myocardial injury (Model 1, Table 4 ). Coronary artery disease showed an association of borderline significance with myocardial injury (OR 2.14, P ¼ 0.053) (Model 1, Table 4 ). The performance of the predictive model was high (Supplementary material online, Table 3 ). In a sensitivity analysis investigating the stability of Model 1, the results were unchanged (Supplementary material online, Table 4 ). In Model 2, the effect of hypertension (OR 1.83, P = 0.055) and of the PaO 2 /FiO 2 ratio (OR 1.23, P = 0.18) on myocardial injury was attenuated, while the strength of evidence for an association between coronary artery disease and myocardial injury increased (OR 2.17, P = 0.048) (Supplementary material online, Table 5 ). Consistent effects with the main analysis were found for the remaining predictors. CAC score was not selected as a predictor in any multivariable model. C-reactive protein did not emerge as a predictor of myocardial injury (Supplementary material online, Table 5 ). The performance of Model 1 was slightly better than that of Model 2 (Supplementary material online, Tables 3 and 6).

In another sensitivity analysis using sex-specific cut-off values of hsTn-I (i.e. 19.8 ng/L for males and 11.6 ng/L for females), the predictors of the main analysis were confirmed, and female sex emerged as an additional predictor of myocardial injury (Supplementary material online, Table 7 ).

Patients with myocardial injury had a longer duration of hospitalization [13 (9-19) vs. 12 (7-17) days, P ¼ 0.028) and a higher frequency of intensive care unit admission (31% vs. 16%, P ¼ 0.002) ( Table 3) . Among patients who remained alive (n = 264), the prevalence of discharged patients was lower in patients with myocardial injury in comparison with patients without myocardial injury (53% vs. 82%, P < 0.001) ( Table 3) . 

Median time to follow-up was 12 days (8-17). As of 10 April 2020, no patient was lost to follow-up. Of 332 patients, 68 (20.5%) died; all deaths occurred in the hospital; 50 (40.6%) deaths occurred in patients with myocardial injury compared with 18 (8.61%) in patients without myocardial injury (P < 0.001). The results from univariable Cox regression analysis for death are displayed in Supplementary material online, Table 8 . By multivariable Cox regression analysis, myocardial injury was an independent predictor of death (HR 2.25, 95% CI 1.27-3.96, P = 0.005, Model 1, Table 5 ) and the adjusted cumulative incidence of death at 30 days was computed to 32.4% (95% CI 19.9-46.6%) in patients with myocardial injury, and to 16.1% (95% CI 8.6-26.2%) in patients without myocardial injury (Figure 1) . Age (HR 1.06, P < 0.001), eGFR (HR 0.98, P = 0.002), PaO 2 /FiO 2 ratio, treated as categorical variable (HR 1.49, P = 0.002), and PA diameter (HR 1.09, P = 0.01) were other independent predictors of death (Model 1). The performance of the predictive model was high (Supplementary material online, Table 9 ). In a sensitivity analysis, we performed a bootstrap stability investigation of Model 1, and the results of the predictive model were unchanged (Supplementary material online, Table 10 ). In another sensitivity analysis, the addition of BNP to Model 1 did not substantially affect the prognostic value of Table 11 ). In a post-hoc exploratory analysis, a cut-off value of 32 mm for PA diameter, selected on the basis of the optimal threshold for sensitivity and specificity, replaced PA diameter as a continuous variable in the multivariable Cox regression model and was associated with an increased adjusted HR of mortality of 1.78 (P = 0.04) (Supplementary material online, Table 12 ).

In another sensitivity analysis, using sex-specific cut-off values of hsTn-I (i.e. 19.8 ng/L for males and 11.6 ng/L for females), the multivariable Cox regression analysis confirmed the predictors of the main analysis (Supplementary material online, Table 13 ).

In this study including 332 patients, admitted to a single-centre academic institution, with laboratory-confirmed COVID-19 undergoing chest CT, myocardial injury occurred in approximately one-third of cases and was independently associated with an approximately two-fold increased risk of death at 30 days by multivariable Cox regression (adjusted HR 2.2, P ¼ 0.005). The predictive value of myocardial injury was consistently confirmed in a number of sensitivity analyses.

Recent studies have reported myocardial injury in patients with COVID-19 and suggested an association between myocardial injury and mortality. 1 patients with myocardial injury than in patients without myocardial injury (59.6% vs. 8.9%) in a study of 187 patients with COVID-19 1 , and found a stepwise increase in mortality when they split the study population into subgroups of patients according to the presence of pre-existing cardiovascular disease alone, myocardial injury alone, or their combination (13.3%, 37.5%, and 69.4%, respectively). 1 Shi et al. also found that myocardial injury was independently associated with mortality, with an adjusted HR of 4.26 (P < 0.001), in a study of 416 patients with COVID-19. 2 Our findings provide strong evidence of a link between myocardial injury and the adjusted risk of death in COVID-19 patients in a different patient population and support the recommendation of a systematic assessment of cardiac troponins for risk stratification of COVID-19 patients regardless of prior comorbidities and the severity of clinical presentation. These findings also underscore the need for future studies assessing whether early initiation of tailored therapies to patients with myocardial injury may improve clinical outcomes. In this regard we found weak evidence that prior use of an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) at the time of admission could be associated with a reduced risk of myocardial injury (adjusted OR 0.52, P = 0.07), as well as of death (adjusted HR 0.68, P = 0.14), by multivariable regression. Recently, inpatient use of ACEIs or ARBs has been shown to be associated with lower risk of all-cause mortality compared with ACEI or ARB non-users in a propensity scorematched analysis of patients hospitalized with COVID-19 (adjusted HR 0.37, P = 0.03). 15 This is the first study to identify an increased PA diameter, as assessed by CT, as an independent predictor of both myocardial injury and mortality in COVID-19 patients. PA diameter has been shown to correlate with the presence of pulmonary hypertension 16 and has been associated with increased mortality in patients with chronic obstructive pulmonary disease. 17 COVID-19 pneumonia is characterized by a systemic inflammatory disorder with a hypercoagulation state, endothelial dysfunction, hypoxic vasoconstriction leading to a hypoxiainducible transcription factor-dependent signalling pathway, that may predispose to acute endothelial damage of the pulmonary circulation, the occurrence of thrombo-embolic phenomena, and/or small vessel thrombosis. 18-20 Although we do not have availability of systematic echocardiographic data, we may hypothesize that the PA diameter may reflect the ongoing damage to the pulmonary circulation leading to right ventricular overload and/or dysfunction and myocardial injury. Of note, a recent systematic echocardiographic study of COVID-19 has shown that patients with elevated Tn-I above the 99th percentile upper reference limit have worse right ventricular function, but do not have any significant difference in left ventricular systolic function compared with patients with normal troponin. 21 Future studies are needed to provide a better understanding of the mechanisms underlying the relationship between pulmonary arterial circulation, right ventricular dysfunction, and myocardial injury, and assess whether early identification and treatment of right-sided heart failure may lead to improved outcomes and reduced mortality in patients with COVID-19. Whether the use of cut-off values of PA diameter, such as the one we identified in our post-hoc exploratory analysis, in conjunction with myocardial injury could provide a useful adjunct to short-term risk estimation of death needs external validation in prospective studies. For example, a patient with both a PA diameter > _32 mm and myocardial injury has an estimated 30-day adjusted risk for death, by multivariable Cox regression, of 47.2%, compared with an estimated risk of 14.6% in a patient with none of these in our cohort. We also identified other factors that were associated with an increased risk of myocardial injury. One possible explanation for the independent association of prior cerebrovascular disease with myocardial injury is that patients with prior cerebrovascular disease may have clinically undetected obstructive coronary artery disease and may be at high risk of myocardial ischaemia and of type 2 myocardial infarction. Indeed, silent myocardial ischaemia on non-invasive tests has been detected in 25-60% of stroke patients without any clinical coronary artery disease, and about a third of patients before carotid surgery had one or more coronary artery stenoses > _70%. 22, 23 History of coronary artery disease was found to have an independent association, albeit weak, with increased risk of myocardial injury in our study. We also explored the predictive value of the CAC score given its correlation with the presence of obstructive angiographic coronary lesions. 24 Nevertheless, the CAC score showed an association with myocardial injury by univariable analysis only, thus indicating that it does not provide incremental value for risk stratification of myocardial injury in patients with COVID-19. We report an independent association of hypertension with an increased risk of myocardial injury that is in agreement with previous evidence. 25 Nevertheless, owing to the lack of systematic use of electrocardiography and echocardiography or cardiovascular magnetic resonance imaging, we could not assess the proportion of patients with myocardial injury who experienced type 2 myocardial infarction, or had direct cardiac involvement due to inflammation including myocarditis, cardiomyopathy, or new ventricular dysfunction. Indeed, cases of myocarditis have been previously reported in COVID-19 patients. [26] [27] [28] We also show that a lower PaO 2 /FiaO 2 ratio on admission, older age, and a lower eGFR were common risk factors for both myocardial injury and death. Shi et al. reported a higher incidence of ARDS in patients with myocardial injury than in those without (58.5% vs. 14.7%; P < 0.001); they found that ARDS was independently associated with mortality, with an adjusted HR of 7.89 (P < 0.001). 2 Taken together, these findings indicate that hypoxic myocardial injury is a prognostically relevant characteristic of cardiac involvement in patients with COVID-19.

Zhou et al. reported older age as an important risk factor for death in patients with COVID-19. 29 An age-dependent increase in the proinflammatory response to viral infection owing to impairment in T-cell and Bcell function has been hypothesized, that may lead to worse outcomes. 30 Finally, the independent association of eGFR with myocardial injury and mortality is in line with the findings from previous studies showing that poor renal function is associated with higher troponin concentrations and that there is an inverse relationship between eGFR and mortality across different patient populations. [31] [32] [33] [34] 

The retrospective design of the study conducted at a hot-spot academic centre of SARS-COV-2 infection with selective inclusion of patients undergoing chest CT scan for the assessment of COVID-19 pneumonia may lead to the selection of a high-risk population, which is reflected by the high mortality rate observed in the case series. It is also difficult to ascertain the causal role of myocardial injury in the occurrence of death in an individual case. We could not assess the right ventricular dimension by CT owing to the lack of contrast administration. Chest CT imaging abnormalities such as focal unilateral or diffuse bilateral ground-glass opacities were not reported in this study.

The absence of haemodynamic and echocardiographic data in the overall study population does not allow us to provide definitive explanations for the observed increased PA diameter in patients with myocardial injury. Indeed, an increased PA diameter might reflect the severity of respiratory compromise and lung involvement, as known to occur in other ARDS conditions. Myocardial injury might reflect the severity of COVID-19 pneumonia.

From a methodological standpoint, strengths of this study are the inclusion of participants who were still in hospital and have neither recovered nor died within the study time period, with the use of appropriate time-to-event analysis to allow for administrative censoring and the absence of loss to follow-up. Further, the performance of the prediction models for cardiac injury and mortality, including discrimination and calibration, was systematically assessed and was high. However, we did not perform an independent external validation of these models; therefore, their generalizability and implementation remain to be addressed in individual participant data from other prospective cohort studies.

This study of hospitalized patients with COVID-19 undergoing chest CT scan shows that myocardial injury, as assessed by cardiac troponins, occurs in approximately one-third of cases, and is associated with an adjusted two-fold increased risk of mortality. An increased PA diameter is an independent predictor of both myocardial injury and mortality. Future studies are needed to elucidate the underlying mechanisms that link a higher pulmonary artery size to myocardial injury and mortality. 

Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)

Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China

Potential effects of coronaviruses on the cardiovascular system: a review

The science underlying COVID-19: implications for the cardiovascular system

Reference values for normal pulmonary artery dimensions by noncontrast cardiac computed tomography: the Framingham Heart Study

Coronary artery calcium scores and atherosclerotic cardiovascular disease risk stratification in smokers

Pulmonary artery enlargement is associated with cardiac injury during severe exacerbations of COPD

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region

The endothelium in acute lung injury/acute respiratory distress syndrome

Coronary calcium score and cardiovascular risk

The adaptive LASSO and its oracle properties

Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19

Performance of pulmonary artery dimensions measured on high-resolution computed tomography scan for identifying pulmonary hypertension

Pulmonary arterial enlargement predicts long-term survival in COPD patients

Coagulopathy and antiphospholipid antibodies in patients with Covid-19

The stimulation of thrombosis by hypoxia

COVID-19 complicated by acute pulmonary embolism and right-sided heart failure

The spectrum of cardiac manifestations in coronavirus disease 2019 (COVID-19)-a systematic echocardiographic study

Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke: a scientific statement for healthcare professionals from the Stroke Council and the Council on

Coronary angiography in 506 patients with extracranial cerebrovascular disease

American College of Cardiology/American Heart Association Expert Consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease

Assessment and classification of patients with myocardial injury and infarction in clinical practice

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Cardiac involvement in a patient with coronavirus 2019 (COVID-19) infection

Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

The immunopathogenesis of sepsis in elderly patients

Interpreting cardiac troponin results from high-sensitivity assays in chronic kidney disease without acute coronary syndrome

High-sensitivity cardiac troponin concentrations in patients with chest discomfort: is it the heart or the kidneys as well?

Cross-sectional study of high-sensitivity cardiac troponins T and I in a hospital and community outpatient setting

High-sensitive cardiac troponin, NT-proBNP, hFABP and copeptin levels in relation to glomerular filtration rates and a medical record of cardiovascular disease

Supplementary material is avilable at Cardiovascular Research online.

G.F., G.C., and L.M. have made substantial contributions to the conception of the work; F.F., O.C., M.M., and L.M. have made substantial contributions to the acquisition of data; R.B. and F.F. performed the echocardiographic analyses; G.F. analysed and interpreted the data, and drafted the work. L.M. and C.G. have revised the work critically. All authors have given their final approval of the version to be published. The corresponding authors take responsibility for all aspects regarding the accuracy or integrity of any part of the work.

The data underlying this article can be shared with researchers who provide a methodologically sound proposal to the corresponding authors for future collaborative research.

This study received COVID-19 funds from Lombardy Region, CARIPLO, Fondazione Umberto Veronesi.

The present study identifies myocardial injury as a clinically relevant independent risk factor for death in the short term in a population of hospitalized patients with laboratory-confirmed COVID-19 outside of China undergoing chest computed tomography for suspected pneumonia on admission.The study also provides novel insights into the risk factors for myocardial injury, showing that an increased pulmonary artery diameter, assessed by chest computed tomography, is an independent predictor of myocardial injury as well as of mortality, suggesting that pulmonary circulation dysfunction is a pivotal pathological event with cardiac implications in COVID-19.